Ambrx Biopharma Inc. (AMAM) |
|
1.775 -0.075 (-4.05%)
|
02-03 14:10 |
|
Open: |
1.85 |
Pre. Close: |
1.85 |
|
High:
|
1.92 |
Low:
|
1.7494 |
|
Volume:
|
252,106 |
Market Cap:
|
69(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 1:44:35 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.71  One year: 3.28 |
| Support: |
Support1: 1.52 Support2: 1.27 |
| Resistance: |
Resistance1: 2.32 Resistance2: 2.8 |
| Pivot: |
1.97  |
| Moving Average: |
MA(5): 1.88 MA(20): 2.04
MA(100): 1.34 MA(250): 2.62 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 7.2 %D(3): 8.1 |
| RSI: |
RSI(14): 46.1 |
| 52-week: |
High: 5.11 Low: 0.37 |
| Average Vol(K): |
3-Month: 3,882 (K) 10-Days: 354 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMAM ] has closed above bottom band by 10.6%. Bollinger Bands are 55% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.92 - 1.94 |
1.94 - 1.94 |
|
Low:
|
1.74 - 1.76 |
1.76 - 1.77 |
|
Close:
|
1.83 - 1.85 |
1.85 - 1.87 |
|
Company Description |
|
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California. |
Headline News |
Fri, 03 Feb 2023
2023-02-03 | NYSE:AMAM | Press Release | Ambrx Biopharma Inc ... - Stockhouse
Wed, 01 Feb 2023
Should You Accumulate Ambrx Biopharma Inc - ADR (AMAM) Stock Wednesday Morning? - InvestorsObserver
Tue, 17 Jan 2023
Ambrx Biopharma: Some Promise, Much Uncertainty (NYSE:AMAM) - Seeking Alpha
Tue, 10 Jan 2023
Is Ambrx Biopharma Inc - ADR (AMAM) Stock a Smart Value Tuesday? - InvestorsObserver
Tue, 10 Jan 2023
Penny Stocks To Buy? 3 With High Short Interest To Watch This Week - Penny Stocks
Tue, 20 Dec 2022
Premarket Mover: Ambrx Biopharma Inc - ADR (AMAM) Down 5.69% - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
39 (M) |
|
% Held by Insiders
|
1.038e+007 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
1,880 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.564e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
487.2 |
|
Return on Equity (ttm)
|
-24.7 |
|
Qtrly Rev. Growth
|
5.24e+006 |
|
Gross Profit (p.s.)
|
0.19 |
|
Sales Per Share
|
0.19 |
|
EBITDA (p.s.)
|
-1.61 |
|
Qtrly Earnings Growth
|
6.5 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-68 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
0 |
|
Price to Sales
|
9.2 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
712130 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
